<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Macrolides: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i166.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i166.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i166.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i127.htm">Antibacterials</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i917.htm" title="Previous: Linezolid">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i167.htm" title="Next: Azithromycin">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i166">Macrolides</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Macrolides</b>
          has the following interaction information:
        </p><div><i>See also</i> Telithromycin</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i937.htm" name="_937">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  macrolides advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i556.htm" name="_556">Bromocriptine</a></td><td> macrolides possibly increase plasma concentration of bromocriptine (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i557.htm" name="_557">Cabergoline</a></td><td> macrolides possibly increase plasma concentration of cabergoline (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i499.htm" name="_499">Ciclosporin</a></td><td class="cBV"><b> macrolides possibly inhibit metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i480.htm" name="_480">Digoxin</a></td><td> macrolides increase plasma concentration of digoxin (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i1152.htm" name="_1152">Droperidol</a></td><td class="cBV"><b>avoidance of  macrolides advised by manufacturer of droperidol (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i563.htm" name="_563">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  macrolides given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i841.htm" name="_841">Mizolastine</a></td><td class="cBV"><b> macrolides possibly inhibit metabolism of mizolastine (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i231.htm" name="_231">Reboxetine</a></td><td class="cBV"><b>avoidance of  macrolides advised by manufacturer of reboxetine </b></td><td></td></tr></tbody></table><p>Macrolides belongs to <b>Antibacterials</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i1058.htm">Typhoid Vaccine (oral)</a></td><td> antibacterials inactivate oral typhoid vaccine—see under Typhoid vaccines, <a title="monograph-family: Typhoid vaccines" href="6528.htm#_6528">section 14.4</a></td><td></td></tr></tbody></table><p><b>Azithromycin</b> belongs to
      <b>Macrolides</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  azithromycin reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> azithromycin possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> azithromycin possibly enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b> azithromycin possibly increases plasma concentration of disopyramide (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td>plasma concentration of  azithromycin increased by nelfinavir (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b>increased risk of side-effects including neutropenia when  azithromycin given with rifabutin </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  azithromycin possibly increased by ritonavir </td><td></td></tr></tbody></table><p><b>Clarithromycin</b> belongs to
      <b>Macrolides</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

















































<tr><td><a href="41001i1010.htm">Aprepitant</a></td><td> clarithromycin possibly increases plasma concentration of aprepitant </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td>plasma concentration of both drugs increased when  clarithromycin given with atazanavir </td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of atorvastatin </b></td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  clarithromycin advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td class="cBV"><b> clarithromycin possibly inhibits metabolism of calcium-channel blockers (increased risk of side-effects)</b></td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> clarithromycin inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> clarithromycin possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> clarithromycin enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b> clarithromycin possibly increases plasma concentration of disopyramide (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>avoidance of  clarithromycin advised by manufacturer of dronedarone (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>increased risk of rash when  clarithromycin given with efavirenz </td><td></td></tr><tr><td><a href="41001i963.htm">Eletriptan</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of etravirine , also plasma concentration of clarithromycin reduced</b></td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> clarithromycin possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1119.htm">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  clarithromycin given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td> clarithromycin increases plasma concentration of itraconazole </td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b> clarithromycin possibly increases plasma concentration of ivabradine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> clarithromycin possibly increases plasma concentration of maraviroc (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i492.htm">Methylprednisolone</a></td><td> clarithromycin possibly increases plasma concentration of methylprednisolone </td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> clarithromycin inhibits metabolism of midazolam (increased plasma concentration  with increased sedation)</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td>plasma concentration of  clarithromycin reduced by nevirapine (but concentration of an active metabolite increased), also plasma concentration of nevirapine increased</td><td></td></tr><tr><td><a href="41001i1118.htm">Nilotinib</a></td><td class="cBV"><b>avoidance of  clarithromycin advised by manufacturer of nilotinib </b></td><td></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td>plasma concentration of both drugs increased when  clarithromycin given with omeprazole </td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  clarithromycin advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> clarithromycin inhibits metabolism of phenytoin (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  clarithromycin given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i604.htm">Pravastatin</a></td><td> clarithromycin increases plasma concentration of pravastatin </td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> clarithromycin possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> clarithromycin possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i855.htm">Repaglinide</a></td><td> clarithromycin enhances effects of repaglinide </td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of rifabutin (increased risk of toxicity—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i199.htm">Rifamycins</a></td><td>plasma concentration of  clarithromycin reduced by rifamycins </td><td>Interactions do not apply to rifaximin</td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  clarithromycin increased by ritonavir (reduce dose of clarithromycin in renal impairment)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  clarithromycin given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td> clarithromycin possibly increases plasma concentration of sildenafil—reduce initial dose of sildenafil</td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  clarithromycin given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of sirolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td> clarithromycin possibly increases plasma concentration of tadalafil </td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of both drugs possibly increased when  clarithromycin given with telaprevir (increased risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td> clarithromycin possibly increases plasma concentration of theophylline </td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td class="cBV"><b> clarithromycin possibly increases plasma concentration of ticagrelor—manufacturer of ticagrelor advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  clarithromycin increased by tipranavir (reduce dose of clarithromycin in renal impairment), also clarithromycin increases plasma concentration of tipranavir</b></td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td>avoidance of  clarithromycin advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i255.htm">Trazodone</a></td><td> clarithromycin possibly increases plasma concentration of trazodone </td><td></td></tr><tr><td><a href="41001i1085.htm">Vinorelbine</a></td><td class="cBV"><b>possible increased risk of neutropenia when  clarithromycin given with vinorelbine </b></td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td> clarithromycin tablets reduce absorption of zidovudine (give at least 2 hours apart)</td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr></tbody></table><p><b>Erythromycin</b> belongs to
      <b>Macrolides</b>
          and has the following interaction information:
        </p><div>Interactions do not apply to small amounts of erythromycin used topically</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






























































<tr><td><a href="41001i86.htm">Alfentanil</a></td><td> erythromycin increases plasma concentration of alfentanil </td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when <i>parenteral</i>  erythromycin given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i809.htm">Amisulpride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  erythromycin given with amisulpride—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1168.htm">Arsenic Trioxide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  erythromycin given with arsenic trioxide </b></td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when <i>parenteral</i>  erythromycin given with atomoxetine </b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  erythromycin given with atorvastatin </td><td></td></tr><tr><td><a href="41001i556.htm">Bromocriptine</a></td><td> erythromycin increases plasma concentration of bromocriptine (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i427.htm">Buspirone</a></td><td> erythromycin increases plasma concentration of buspirone (reduce dose of buspirone)</td><td></td></tr><tr><td><a href="41001i557.htm">Cabergoline</a></td><td> erythromycin increases plasma concentration of cabergoline (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td class="cBV"><b> erythromycin possibly inhibits metabolism of calcium-channel blockers (increased risk of side-effects)</b></td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> erythromycin increases plasma concentration of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> erythromycin inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i940.htm">Cilostazol</a></td><td> erythromycin increases plasma concentration of cilostazol (consider reducing dose of cilostazol)</td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  erythromycin increased by cimetidine (increased risk of toxicity, including deafness)</td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> erythromycin possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b> erythromycin possibly increases plasma concentration of clozapine (possible increased risk of convulsions)</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> erythromycin possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td> erythromycin possibly inhibits metabolism of corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> erythromycin enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td> erythromycin possibly increases plasma concentration of darifenacin </td><td></td></tr><tr><td><a href="41001i1172.htm">Dienogest</a></td><td> erythromycin increases plasma concentration of dienogest </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b> erythromycin increases plasma concentration of disopyramide (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i516.htm">Docetaxel</a></td><td><i>in vitro</i> studies suggest a possible interaction between  erythromycin and docetaxel (consult docetaxel product literature)</td><td></td></tr><tr><td><a href="41001i553.htm">Domperidone</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  erythromycin given with domperidone </b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b> erythromycin increases plasma concentration of dronedarone (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i963.htm">Eletriptan</a></td><td class="cBV"><b> erythromycin increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td> erythromycin increases plasma concentration of eplerenone (reduce dose of eplerenone)</td><td></td></tr><tr><td><a href="41001i640.htm">Estradiol</a></td><td> erythromycin increases plasma concentration of estradiol </td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> erythromycin increases plasma concentration of everolimus </b></td><td></td></tr><tr><td><a href="41001i915.htm">Galantamine</a></td><td> erythromycin increases plasma concentration of galantamine </td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  erythromycin given with ivabradine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i846.htm">Lercanidipine</a></td><td>avoidance of  erythromycin advised by manufacturer of lercanidipine </td><td></td></tr><tr><td><a href="41001i309.htm">Loratadine</a></td><td>manufacturer of loratadine advises  erythromycin possibly increases plasma concentration of loratadine </td><td></td></tr><tr><td><a href="41001i492.htm">Methylprednisolone</a></td><td> erythromycin inhibits the metabolism of methylprednisolone </td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> erythromycin inhibits metabolism of midazolam (increased plasma concentration  with increased sedation)</b></td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b> erythromycin inhibits metabolism of mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when <i>parenteral</i>  erythromycin given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when <i>parenteral</i>  erythromycin given with pentamidine isetionate </b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  erythromycin given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i604.htm">Pravastatin</a></td><td> erythromycin increases plasma concentration of pravastatin </td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> erythromycin increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> erythromycin possibly increases plasma concentration of rifabutin (increased risk of toxicity—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  erythromycin possibly increased by ritonavir </td><td></td></tr><tr><td><a href="41001i974.htm">Rosuvastatin</a></td><td> erythromycin reduces plasma concentration of rosuvastatin </td><td></td></tr><tr><td><a href="41001i1155.htm">Rupatadine</a></td><td> erythromycin increases plasma concentration of rupatadine </td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  erythromycin given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td> erythromycin increases plasma concentration of sildenafil—reduce initial dose of sildenafil</td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  erythromycin given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b>plasma concentration of both drugs increased when  erythromycin given with sirolimus </b></td><td></td></tr><tr><td><a href="41001i371.htm">Sulpiride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when <i>parenteral</i>  erythromycin given with sulpiride </b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> erythromycin increases plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td> erythromycin possibly increases plasma concentration of tadalafil </td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of both drugs possibly increased when  erythromycin given with telaprevir (increased risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> erythromycin increases plasma concentration of theophylline (also theophylline may reduce absorption of <i>oral</i> erythromycin)</b></td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td> erythromycin possibly increases plasma concentration of ticagrelor </td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td>avoidance of  erythromycin advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td> erythromycin possibly inhibits metabolism of valproate (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td> erythromycin increases plasma concentration of vardenafil (reduce dose of vardenafil)</td><td></td></tr><tr><td><a href="41001i1002.htm">Vinblastine</a></td><td class="cBV"><b> erythromycin increases toxicity of vinblastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i859.htm">Zafirlukast</a></td><td> erythromycin reduces plasma concentration of zafirlukast </td><td></td></tr><tr><td><a href="41001i426.htm">Zopiclone</a></td><td> erythromycin inhibits the metabolism of zopiclone </td><td></td></tr><tr><td><a href="41001i390.htm">Zuclopenthixol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when <i>parenteral</i>  erythromycin given with zuclopenthixol—avoid concomitant use</b></td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i167.htm" title="Azithromycin">Azithromycin</a></li><li><a href="41001i168.htm" title="Clarithromycin">Clarithromycin</a></li><li><a href="41001i169.htm" title="Erythromycin">Erythromycin</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i917.htm">Previous: Linezolid</a> | <a class="top" href="41001i166.htm#">Top</a> | <a accesskey="]" href="41001i167.htm">Next: Azithromycin</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>